Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab versus Rituximab in Childhood Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome
2022-003336-59Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in Idiopathic nephrotic syndrome (INS) and nephrosis comparing Obinutuzumab arm with Rituximab arm (2 arms). Primary endpoint: Relapse-free survival at 12 months. Started Oct 2024; status: active.
02
Drugs
obinutuzumabrituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)nephrosis
Beyond the preview
Go deeper on 2022-003336-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003336-59.